S2331 The Efficacy and Safety of Vonoprazan-Based Regimens for Helicobacter pylori Eradication Treatment: A Systemic Review and Network Meta-Analysis

作者：Cangui Zhang, Bingyun Lu, Li Xie, Xi Ran, Ye Chen · 发表于：The American Journal of Gastroenterology · 年份：2024 · DOI：10.14309/01.ajg.0001038692.14851.0f · 研究领域：Helicobacter pylori-related gastroenterology studies、Gastric Cancer Management and Outcomes

Introduction: Helicobacter pylori (Hp) infection is a public health concern due to its high disease burden and complications, emphasizing the crucial need for effective eradication therapy. While vonoprazan (VPZ)-based treatments show promising outcomes, there remains a significant dearth of comprehensive data evaluating their effectiveness and safety worldwide, as well as their performance against proton pump inhibitor (PPI)-based treatments. This review aims to provide guidance for Hp eradication in clinical practice. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, CNKI, Wanfang, VIP, and CBM from inception to 9th January, 2024. Randomized controlled trials (RCTs) involving adult patients investigating VPZ and PPI-based dual, triple, and quadruple treatments were included. Each RCT comprised at least 1 arm receiving VPZ-based regimens. The eradication rate of VPZ-based regimens was analyzed using proportional meta-analysis. Network meta-analysis employing a Bayesian hierarchical random-effects model was performed to compare eradication rates and adverse events between groups. Results: Forty-three studies with 11,043 patients were analyzed, revealing eradication rates of 85.89% for VPZ-dual, 86.38% for VPZ-triple, and 91.00% for VPZ-quadruple regimens, 84.00% for PPI-dual, 78.68% for PPI-triple, and 82.33% for PPI-quadruple regimens. In terms of surfaces under cumulative ranking curve (SUCRA) for eradication rate, VPZ-quadr...